Latest stories
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development 12 February 2024
- Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA Insight, Corporate 28 August 2024 Bringing Better Health Within Reach: Improving access to medicine as the partner of choice in MENA
- Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day Press Release, Product 20 August 2024 Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day
- KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months Press Release, Product 15 August 2024 KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months
- Hikma delivers strong H1 performance and upgrades Group guidance Press Release, Financial Results 08 August 2024 Hikma delivers strong H1 performance and upgrades Group guidance
Related content